From the Editor

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 5
Volume 17
Issue 5

To better engage our readership on the economic, policy, and practice issues affecting the oncology community, we have updated our editorial and changed our name, bringing more value-added content to the pages of Cancer Care Practice & Policy (CCP&P).

To better engage our readership on the economic, policy, and practice issues affecting the oncology community, we have updated our editorial and changed our name, bringing more value-added content to the pages of Cancer Care Practice & Policy (CCP&P). In the upcoming issues, our editors will develop regular columns on topics ranging from billing & coding problems to legal advice and practice management tips, all of which are designed to give quick-reading, issue-solving information for today’s busy oncologists.

Along with the regular feature departments, we will also report on the broader political actions and initiatives that influence the practice of oncology. To that end, we will continue to build our working relationship with ASCO, ASH, and ACCC to deliver consensus-driven views from leading experts on issues such as the impending work-force shortage of medical and gynecological oncologists, the challenges of implementing HIT, cancer care quality initiatives, and regulatory and advocacy issues.

As always, we encourage our readers to share their thoughts, advice, or opinions about anything that appears on these pages. [Please send comments to: Ronald.Piana@cmpmedica.com.]

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.